Collectively, these findings uncover a phase separation‐centric mechanism by which HHT exerts anti‐AML activity, establish the EWSR1–YTHDF2–m6A axis as a critical regulator of leukemia progression, and position EWSR1 as both a functional target and a predictive biomarker for optimizing HHT‐based therapies. This evidence concerns the gene YTHDF2 and leukemia.